Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C

SpringerPlus

Volumn 2, Issue 1, 2013, Pages

  Moritou, Yuki ^a   Ikeda, Fusao ^a   Iwasaki, Yoshiaki ^b   Baba, Nobuyuki ^c   Takaguchi, Kouichi ^c   Senoh, Tomonori ^c   Nagano, Takuya ^c   Takeuchi, Yasuto ^a   Yasunaka, Tetsuya ^a   Ohnishi, Hideki ^a   Miyake, Yasuhiro ^a   Takaki, Akinobu ^a   Nouso, Kazuhiro ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

HCC; HCV; Interferon; PNPLA3

Indexed keywords

EID: 84878773083     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-251     Document Type: Article

References (24)

1. Clark PJ, Thompson AJ, Zhu Q, Vock DM, Zhu M, Patel K, Harrison SA, Naggie S, Ge D, Tillmann HL, Urban TJ, Shianna K, Fellay J, Goodman Z, Noviello S, Pedicone LD, Afdhal N, Sulkowski M, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ (2012) The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci 57:2213-2221.
2. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513-1520.
3. Firpi RJ, Nelson DR (2007) Current and future hepatitis C therapies. Arch Med Res 38:678- 690.
4. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver Diseases (2011a) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54:1433-1444.
5. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver D (2011b) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54:1433-1444.
6. He S, McPhaul C, Li JZ, Garuti R, Kinch LN, Grishin NV et al (2009) A sequence variation (I148M) in PNPlA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 285:6706-6715.
7. Ikeda F, Dansako H, Nishimura G, Mori K, Kawai Y, Ariumi Y et al (2010) Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon-α in vitro. Liver Int 30:1324-1331.
8. Imai Y, Kawata S, Tamura S et al (1998) Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 129:94-99.
9. Kato N (2001) Molecular virology of hepatitis C virus. Acta Med Okayama 55:133-159.
10. Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M, Watanabe S, Kawata S, Imai Y, Kokubo M, Shima T, Park H, Tanaka H, Tajima K, Yamada R, Matsuda F, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (2012) Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 7:e38322.
11. Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, Hamsten A et al (2009) A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 52:1056-1060.
12. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N (2012) Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 56:78-84.
13. Makuuchi M, Kokudo N, Arii S (2010) Clinical practice guidelines for hepatocellular carcinoma - the Japan society of hepatology 2009 update. Hepatol Res 40:2-144.
14. Miyashita M, Ito T, Sakaki M, Kajiwara A, Nozawa H, Hiroishi K, Kobayashi M, Kumada H, Imawari M (2012) Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C. J Viral Hepat 19:608-614.
15. Nishiguchi S, Shiomi S, Nakatani S et al (2001) Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357:196-197.
16. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38:75-85.
17. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461-1465.
18. Takeuchi Y, Ikeda F, Moritou Y, Hagihara H, Yasunaka T, Kuwaki K, Miyake Y, Ohnishi H, Nakamura S, Shiraha H, Takaki A, Iwasaki Y, Nouso K, Yamamoto K (2013) The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol 48:405-412.
19. Trépo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, Lemmers A, Berthillon P, Amininejad L, Chevallier M, Schlué J, Kreipe H, Devière J, Manns M, Trépo C, Sninsky J, Wedemeyer H, Franchimont D, Moreno C (2011) Impact of patatin-like phospholipase-3 (rs738409. C > G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 54:60-69.
20. Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio A, Dongiovanni P, Fargion S, Nobili V (2010) I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 52:1274-1280.
21. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S (2011) Patatin-like phospholipase domain-containing 3. I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53:791-799.
22. Valenti L, Aghemo A, Stättermayer AF, Maggioni P, De Nicola S, Motta BM, Rumi MG, Dongiovanni P, Ferenci P, Colombo M, Fargion S (2012) Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol Ther 35:1434-1442.
23. Yoshida H, Shiratori Y, Moriyama M et al (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C. Ann Intern Med 131:174-181.
24. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364:2417-2428